Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...

Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

NEW YORK (Reuters) - About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% ...

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...

Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday ...

Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.

it took another four years for Wegovy to be approved for weight loss. It turned Novo Nordisk from niche player, to a company bigger than Coca Cola and Procter and Gamble… The CEO is Lars ...

LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%.